Tocilizumab is an interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.
- Mechanism
- Curator reviewed · 4 references
Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts. IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and α-1-antichymotrypsin while inhibiting production of fibronectin, albumin, and transferrin. IL-6 also induces antibody production, induces cytotoxic T-cell differentiation, and inhibits regulatory T-cell differentiation. Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.
- Primary indication
- Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.Curator reviewed · 20 structured indications
- Formula / weight
- C6428H9976N1720O2018S42 · 148000.0 Da
- First approval
- Canada, 2010 · United States, 2010 · European Union, 2020
- Also known as
- Atlizumab · BAT1806 · ROACTEMRA · tocilizumab-aazg · Tocilizumab-anoh
- Code names
- MRA · MSB-11456 · R-1569 · RG-1569 · RHPM-1 · RO-4877533
- Brand names
Resolves to
What you can answer from here — as of September 05, 2026
Which drugs share a target with Tocilizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account